Inhibition of the anti-apoptotic protein BCL2 in EML4-ALK cell models as a second proposed therapeutic target for non-small cell lung cancer.
The anaplastic lymphoma kinase (ALK) oncoprotein plays a crucial role in non-small cell lung cancer (NSCLC) by activating signaling pathways involved in cell proliferation and survival through constitutive phosphorylation. While first-line crizotinib can regulate phosphorylation, mutations in the AL...
Saved in:
Main Authors: | Richard Junior Zapata Dongo, Diletta Fontana, Luca Mologni, Juan Enrique Faya Castillo, Stefany Fiorella Infante Varillas |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2025-01-01
|
Series: | PLoS ONE |
Online Access: | https://doi.org/10.1371/journal.pone.0308747 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Inhibition of the anti-apoptotic protein BCL2 in EML4-ALK cell models as a second proposed therapeutic target for non-small cell lung cancer
by: Richard Junior Zapata Dongo, et al.
Published: (2025-01-01) -
Small cell lung cancer with EML4-ALK fusion: report of a case responding to ALK TKI and literature review
by: Mingyue Wang, et al.
Published: (2025-02-01) -
Impact of EML4‐ALK Variants and TP53 Status on the Efficacy of ALK Inhibitors in Patients With Non‐small Cell Lung Cancer
by: Zihua Zou, et al.
Published: (2025-01-01) -
EML4‐ALK‐Positive Ovarian Cancer With Intracranial Metastasis Responds to Lorlatinib: A Case Report and Literature Review
by: Qiongqian Li, et al.
Published: (2025-01-01) -
Developing and Activated T Cell Survival Depends on Differential Signaling Pathways to Regulate Anti-Apoptotic Bcl-xL
by: Ruiqing Wang, et al.
Published: (2012-01-01)